Key Highlights

Risk & Performance

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

1 recruiting

Phase 1

4(80.0%)

Phase 3

1(20.0%)

5Total

Phase 1(4)

Phase 3(1)

Loading network data...

Showing 5 of 5 trials

Filling Bone Defects/Voids With Autologous BonoFill-II for Maxillofacial Bone Regeneration

Role: lead

Enhancement of Bone Regeneration and Healing in the Extremities by the Use of Autologous BonoFill-II

Role: lead

Safety and the Efficacy of MesenCure for the Treatment of Pulmonary Manifestations of COVID-19

Role: lead

A Controlled Study to Evaluate the Efficacy of Allogeneic MesenCure for the Treatment of Patients With ARDS

Role: lead

Filling Bone Defects/Voids With Autologous BonoFill For Maxillofacial Bone Regeneration

Role: lead

All 5 trials loaded